Prognostic significance of positron emission tomography (PET) prior to stem cell transplantation.
| . | . | . | . | . | . | . | . | PFS@2 year* . | |
|---|---|---|---|---|---|---|---|---|---|
| Author (ref) . | No. . | Histology . | Indication SCT . | Timing PET . | Definition PET Response . | PPV . | NPV . | PET Response . | PET Non-Resp. . |
| * estimated from Kaplan Meier plots | |||||||||
| Abbreviations: SCT, stem cell transplantation; PPV, positive predictive value; NPV, negative predictive value; PFS, progression-free survival; HD, Hodgkin’s disease; NHL, non-Hodgkin’s lymphoma | |||||||||
| Becherer (29) | 16 | HD/NHL | not spec | prior to SCT | no or minimal residual disease | 87% | 87% | 88% | 18% |
| Cremerius (30) | 22 | NHL | first-line | prior | > 25% decrease to SCT | 86% | 67% | 72% | 28% |
| Filmont (31) | 20 | HD/NHL | first | prior relapse | no residual disease to SCT | 92% | 87% | 88% | 8% |
| Schot (32) | 46 | HD/NHL | first | mid relapse | no residual disease induction | 65% | 67% | 62% | 38% |
| Spaepen (33) | 60 | HD/NHL | first | prior relapse | no residual disease to SCT | 87% | 90% | 100% | 24% |
| . | . | . | . | . | . | . | . | PFS@2 year* . | |
|---|---|---|---|---|---|---|---|---|---|
| Author (ref) . | No. . | Histology . | Indication SCT . | Timing PET . | Definition PET Response . | PPV . | NPV . | PET Response . | PET Non-Resp. . |
| * estimated from Kaplan Meier plots | |||||||||
| Abbreviations: SCT, stem cell transplantation; PPV, positive predictive value; NPV, negative predictive value; PFS, progression-free survival; HD, Hodgkin’s disease; NHL, non-Hodgkin’s lymphoma | |||||||||
| Becherer (29) | 16 | HD/NHL | not spec | prior to SCT | no or minimal residual disease | 87% | 87% | 88% | 18% |
| Cremerius (30) | 22 | NHL | first-line | prior | > 25% decrease to SCT | 86% | 67% | 72% | 28% |
| Filmont (31) | 20 | HD/NHL | first | prior relapse | no residual disease to SCT | 92% | 87% | 88% | 8% |
| Schot (32) | 46 | HD/NHL | first | mid relapse | no residual disease induction | 65% | 67% | 62% | 38% |
| Spaepen (33) | 60 | HD/NHL | first | prior relapse | no residual disease to SCT | 87% | 90% | 100% | 24% |